MEMO Therapeutics raises CHF 5 million in Series A2 Financing Round

VISCHER advises Memo Therapeutics, a Basel based spin-off company from the ETH Zurich, whose proprietary MemoMABTM technology constitutes a disruptive platform technology for antibody discovery. This technology allows to create an authentic copy of whole antibody repertoire of human and animal species in recombinant form. 

The CHF 5 million Series A2 financing round was led by Redalpine, Schroder Adveq, and other Swiss investors. The proceeds will be used to further develop the proprietary MemoMABTM technology and to progress MEMO Therapeutics' antibody candidates in the fields of immuno-oncology and infectious diseases towards clinical trials. 

The team at VISCHER was led by Matthias Staehelin (Partner) and supported by Dania Salvisberg-Schneider (Senior Associate), both Corporate.

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.

Learn more …

News Alerts

Here you will find the frequent news alerts in the fields tax, litigation and arbitration, public sector and regulatory, corporate and commercial law and intellectual property law.

Learn more

Subscribe to news alert


Schützengasse 1, Postfach, 8021 Zürich
Phone +41 58 211 34 00

Aeschenvorstadt 4, Postfach, 4010 Basel
Phone +41 58 211 33 00

Map and Directions